Ipv vaccines market

IPV Vaccines Market, by Vaccine Brand (POLIOVAC (PFS/SD), SHANIPV, POLIORIX, IPOL/IMOVAX, And POLYMILEX), by Distribution Channel (Private and Public), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2024 - 2031

Request Free Sample

Mar 2024
CMI4965
220 Pages
Excel & Pdf
Biotechnology

Summary

The IPV are very safe. At the site of injection pain or mild redness may occur. To preventfrom Poliomyelitis, which affects children under age of 5. This infection can turn into irreversible paralysis and can also cause death. There are two types of vaccines used: an inactivated poliovirus given by injection (IPV) and a weakened poliovirus given orally (OPV). After two doses of inactivated polio vaccine, 90% or more of individuals develop protective antibodies to all three serotypes, when inactivated polio vaccine injection is used and about 99% are immune to polio virus.

Immunity induced by IPV and its duration is not known with certainty, although to provide protection for several years the complete study has been done. In 1990s IPV replaced the oral vaccines due to risk of vaccine-derived polio in oral vaccines in various countries.

The global IPV vaccines market is estimated to be valued at USD 199.6 Mn in 2024 and is expected to exhibit a CAGR of 8.5% during the forecast period (2024-2031).

Figure 1. Global IPV Vaccines Market Value (USD Mn), by Region, 2024

IPV Vaccines Market Report Coverage

Report Coverage	Details
Base Year:	2023	Market Size in 2024:	US$ 199.6 Mn
Historical Data for:	2019 to 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	8.5%	2031 Value Projection:	US$ 352.4 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Vaccine Brand: Poliovac (Pfs/Sd), Shanipv, Poliorix, Ipol/Imovax, Polymilex By Distribution Channel: Private, Public
Companies covered:	GlaxoSmithKline Plc, Sanofi S.A., Serum Institute of India Pvt. Ltd., PT Bio Farma, and AJ Vaccines
Growth Drivers:	Rising government support to increase immunization Increasing initiatives by key players to develop and launch inactivated polio vaccines High demand for inactivated polio vaccines (IPV)
Restraints & Challenges:	Side effects associated with immunization and high cost of inactivated polio vaccines Introduction of combination vaccines
Opportunities:	GAVI (Global Alliance for Vaccines and Immunizations) support to eradicate polio

Figure 2. Global IPV Vaccines Market Share, By Vaccine Brand, 2024

Recent Developments

On January 30, 2024, the United Nations Children's Fund (UNICEF), an agency of the United Nations in charge of providing humanitarian and developmental aid to children around the world, with support from the United States Agency for International Development (USAID), delivered 340,000 doses of the oral polio vaccine (OPV) to Ukraine, bolstering the country's National Immunization Program and protecting children from a life-threatening disease.

In June 2023, the United Nations Children's Fund announced the delivery of 156,960 doses of inactivated polio vaccine (IPV) to support Ukraine's National Immunization Programme, which aims to protect children from the deadly disease.

In December 2022, Sudan's Federal Ministry of Health, in collaboration with the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF), initiated a catch-up vaccination program to immunize children against polio and yellow fever from December 29, 2022 to January 3, 2023.

In September 2020, Sanofi Pasteur India, Sanofi's global vaccines business segment, announced the launch of Tetraxim (DTaP-IPV). The booster vaccine is recommended for preschoolers and protects against four important diseases: diphtheria, pertussis, tetanus, and polio. Tetraxim combines four vaccines into one, minimizing the number of injections required, enhancing child comfort and vaccination compliance, and reducing parental anxiety.

In June 2020, Batavia Biosciences, a CDMO for Viral Vectors and Viral Vaccines, and Valneva Sweden AB, a Sweden-based subsidiary of Valneva SE, a specialty vaccine company announced that they have entered into a collaboration agreement to speed market access for a low-cost inactivated polio vaccine (IPV). According to the terms of the collaboration, Valneva SEwill use Batavia Biosciences’ technique to manufacture the Sabin vaccine strains (sIPV) vaccine for clinical trials at its cutting-edge GMP polio production facility in Solna, Sweden, which is run under GAPIII polio containment.

Global IPV Vaccines Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic is the most recent outbreak, which was first reported on December 31, 2019, in Wuhan, China. The shutdown disrupted the supply, distribution, and manufacturing of medical supplies globally. Moreover, due to social distancing, the footfall in clinics and health institutions has fallen by more than 70% during this pandemic, which has led to decrease in the number of surgical procedures, clinical trials, research and development activities and others, which has negatively impacted the market growth.

Vaccine hesitancy has been considered a problem for polio eradication in past for Pakistan and Afghanistan. The COVID-19 vaccines had made a widespread awareness regarding lifesaving effects of the vaccines, and this effected on the public awareness in polio endemic countries (Gabon, Ghana, Guinea, Liberia, Nigeria). Especially in the tropics there is need for booster doses of polio vaccine. In routine immunizations, there is need to implement GPEIs, for the oral polio vaccines, which can help in reducing the polio cases by more than 90%. To protect the lives of children, the COVID-19 vaccination centers remain ideal to increase the awareness of polio vaccines.

Global IPV Vaccines Market - Restraint

Inactivated polio vaccines are given to millions of children and adults for the prevention of polio. Although, in some cases, this immunization shows side effects including: rash, itching.

According to several research studies, immunization with inactivated polio vaccines are less effective. For instance, inactivated polio vaccines (IPV) weaken immunity in the intestine. Moreover, after immunization with IPV, every person gets infected with wild poliovirus, which multiply in the intestines.

Therefore, these side effects can pose major challenges such as decreasing community acceptance for such inactivated polio vaccines, which in turn is expected to hamper growth of Global Inactivated Polio Vaccines Market.

High cost of inactivated polio vaccines in comparison with oral polio vaccines may negatively impact growth of the inactivated polio vaccines market.

For instance, in 2019, according to the World Health Organization, the weighted average price of IPV vaccines per dose is US$ 2.8 while the price per dose of OPV vaccine ranges from US$ 0.12 to 0.17 in PAHO countries.

Key Players

Major players operating in the Global IPV vaccines market include GlaxoSmithKline Plc, Sanofi S.A., Serum Institute of India Pvt. Ltd., PT Bio Farma, and AJ Vaccines.

Table of Content

Table of Contents

Segmentation

Detailed Segmentation:

Global IPV Vaccines Market, by Vaccine Brand:
- Poliovac (Pfs/Sd)
- Shanipv
- Poliorix
- Ipol/Imovax
- Polymilex
Global IPV Vaccines Market, by Distribution Channel:
- Private
- Public
Global IPV Vaccines Market, by Region:
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - GCC
  - Israel
  - Rest of Middle East
- Africa
  - South Africa
  - Central Africa
  - North Africa

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the market during the forecast period (2024-2031)?

The global IPV vaccines market size is estimated to be valued at USD 199.6 MN in 2024 and is expected to exhibit a CAGR of 8.5% between 2024 and 2031.

What are the major factors driving the market growth?

The rising government support to increase immunization, increasing initiatives by key players to develop and launch inactivated polio vaccines, and high demand for inactivated polio vaccines (IPV) are the major factors which are expected to drive the market growth over the forecast period.

Which is the leading vaccine brand segment in the market in 2024?

IPOL/IMOVAX is expected to hold major market share over the forecast period.

What are the key factors hampering the growth of the market?

Major factors hampering growth of the global IPV vaccines market include side effects associated with immunization, high cost of inactivated polio vaccines, and introduction of combination vaccines.

Which are the major players operating in the market?

Major players operating in the market are Sanofi, Serum Institute of India Pvt. Ltd., Bharat Biotech, Merck & Co., Inc., GlaxoSmithKline, AJ Vaccines A/S, Panacea Biotec, Biken, Sinopharm Group Co. Ltd., Nanolek, IMBCAMS, Sinovac Biotech, LG Chem, Beijing Minhai Biological Technology Co., Ltd., and Biological E Limited.